ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.63 USD 1.54% Market Closed
Market Cap: 278.5m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note

Relative Value

The Relative Value of one PRQR stock under the Base Case scenario is 2.72 USD. Compared to the current market price of 2.63 USD, ProQR Therapeutics NV is Undervalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRQR Relative Value
Base Case
2.72 USD
Undervaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
45
Median 3Y
24.8
Median 5Y
40.4
Industry
7.6
Forward
12.1
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-7.8
Industry
22.1
Forward
-8
vs History
vs Industry
12
Median 3Y
-4
Median 5Y
-7.8
Industry
21.9
vs History
vs Industry
10
Median 3Y
-4.3
Median 5Y
-7.3
Industry
23.4
vs History
0
vs Industry
23
Median 3Y
4.2
Median 5Y
5.1
Industry
2.5
vs History
55
vs Industry
60
Median 3Y
9.4
Median 5Y
24.5
Industry
7.5
Forward
8.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
vs Industry
33
Median 3Y
-3
Median 5Y
-4.9
Industry
4.2
Forward
-4.5
vs History
vs Industry
32
Median 3Y
-2.8
Median 5Y
-4.5
Industry
4
Forward
-4.6
vs History
vs Industry
14
Median 3Y
-2.3
Median 5Y
-6.1
Industry
5.9
vs History
vs Industry
11
Median 3Y
-2.2
Median 5Y
-5.9
Industry
3.9
vs History
31
vs Industry
45
Median 3Y
3.6
Median 5Y
6.4
Industry
4.5

Multiples Across Competitors

PRQR Competitors Multiples
ProQR Therapeutics NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
ProQR Therapeutics NV
NASDAQ:PRQR
278.5m USD 12.5 -11.1 -7.9 -7.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.8B EUR 19.2 -134.7 -108.8 -79.3
P/S Multiple
Revenue Growth P/S to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average P/S: 3 457 241.1
12.5
82%
0.2
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average P/E: 211.7
Negative Multiple: -11.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average EV/EBITDA: 16.2
Negative Multiple: -7.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average EV/EBIT: 21.2
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.3 N/A N/A

See Also

Discover More
Back to Top